Helen K. Ellias is a director of SAB Biotherapeutics Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Nov 23 | SABS SAB Biotherapeutics | Common Stock | Option exercise | Acquire M | Yes | No | 0 | 2,857,142 | 0.00 | 2,857,142 |
24 Nov 23 | SABS SAB Biotherapeutics | Series A-1 Convertible Preferred Stock Common Stock or Series A-2 Convertible Preferred Stock | Option exercise | Dispose M | Yes | No | 1000 | 1,800 | 1.80 mm | 0 |